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Abstract
Objective: We aimed to estimate the maximum intervention cost (EMIC) a society could invest in a life-saving
intervention at different ages while remaining cost-effective according to a user-specified cost-effectiveness
threshold.
Methods: New Zealand (NZ) was used as a case study, and a health system perspective was taken. Data from NZ
life tables and morbidity data from a burden of disease study were used to estimate health-adjusted life-years
(HALYs) gained by a life-saving intervention. Health system costs were estimated from a national database of all
publicly funded health events (hospitalizations, outpatient events, pharmaceuticals, etc.). For illustrative purposes we
followed the WHO-CHOICE approach and used a cost-effectiveness threshold of the gross domestic product (GDP)
per capita (NZ$45,000 or US$30,000 per HALY). We then calculated EMICs for an “ideal” life-saving intervention that
fully returned survivors to the same average morbidity, mortality, and cost trajectories as the rest of their cohort.
Findings: The EMIC of the “ideal” life-saving intervention varied markedly by age: NZ$1.3 million (US$880,000) for
an intervention to save the life of a child, NZ$0.8 million (US$540,000) for a 50-year-old, and NZ$0.235 million
(US$158,000) for an 80-year-old. These results were predictably very sensitive to the choice of discount rate and
to the selected cost-effectiveness threshold. Using WHO data, we produced an online calculator to allow the
performance of similar calculations for all other countries.
Conclusions: We present an approach to estimating maximal cost-effective investment in life-saving health
interventions, under various assumptions. Our online calculator allows this approach to be applied in other
countries. Policymakers could use these estimates as a rapid screening tool to determine if more detailed
cost-effectiveness analyses of potential life-saving interventions might be worthwhile or which proposed
life-saving interventions are very unlikely to benefit from such additional research.
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Introduction
Many countries spend a substantial proportion of their
gross domestic product (GDP) on health, e.g., at least
10 % in high-income countries such as New Zealand
[1, 2]. The rapid rise in health spending at a rate faster
than GDP growth (due to income growth, techno-
logical change, population growth, and aging), is un-
likely to be tenable in the long term [3–5]. Hence
policymakers in health, as in other sectors, need to
take increasing care in allocating finite health resources in
ways that maximize health benefits for the population.
In the ideal world policymakers would probably have
the results of studies that identified the country-specific
willingness-to-pay value that society places on saving a
life at different ages. In such an ideal world, they may
also have a methodologically compatible league table of
life-saving and health-gaining interventions – to inform
the “next best” intervention to adopt from a cost-
effectiveness perspective within a government’s available
health budget. But most countries are a long way from hav-
ing such information available, and indeed they often have
limited resources for conducting new cost-effectiveness
analyses (which can take many months and cost tens of
thousands of dollars per intervention modeled).
Given these problems we aimed to provide information
to inform policymakers so that they could more readily
determine if more detailed cost-effectiveness analyses of
potential life-saving interventions might be worthwhile or
which proposed interventions are very unlikely to benefit
from such additional research. We just focus here on the
issue of cost-effectiveness but note that this is just one
component of appropriate decision-making and that many
other components [6–12] might reasonably be weighted
as also being important, e.g., equity impacts, public ac-
ceptability, feasibility, and impact on non-health co-
benefits (e.g., greenhouse gas reductions).
We selected New Zealand as a case study country given
that it has recently completed a national burden of disease
study [13] and has recently produced detailed estimates of
health system costs by age group [14]. Furthermore, it is
like most countries in having no official threshold for de-
termining what is cost-effective in the health sector and so
has to rely on crude measures such as the GDP per capita
expenditure to gain a QALY (as used in recent New
Zealand-based studies, e.g., [15, 16]). It is also a country
where cost-effectiveness considerations might sometimes
appropriately be outweighed by concerns for achieving
health equity, given the need to improve health for the
Māori (indigenous) population [17].
Methods
Our specific aim in this study was to estimate the max-
imum amount society could invest up front in a hypo-
thetical life-saving health intervention at different ages
while remaining cost-effective. For the rest of this paper,
we term this upfront amount “estimated maximum
intervention cost,” or EMIC. For the “ideal intervention”
EMIC, the death prevented is not one from a pre-
existing chronic disease that shortens life expectancy.
Rather, it is death from a relatively acute, “short and
sharp” disease or injury, where the treatment saves the
person’s life and then returns them to expected health,
having the same average morbidity and mortality as the
average citizen of their age and sex. This approach can
be used to estimate the maximum amount society
should spend (for different ages) on treatment interven-
tions for acute conditions such as life-threatening infec-
tious diseases or highly treatable cancers of relatively
short duration such as testicular cancer. Such an analysis
requires data on the health-adjusted life expectancy of
the average citizen and the future stream of health
spending that they will consume over their lifetime.
A cost-effectiveness threshold (CET) is the amount of
money that society is willing to pay for an additional
unit of health gain, usually one quality-adjusted life-year
(QALY) gained [18], or one disability-adjusted life-year
(DALY) averted. We note, however, that there is no uni-
versal agreement on estimates of a cost-effectiveness
threshold [19–22], how these estimates should be de-
rived [23, 24], or even whether a fixed threshold should
be kept at all [25]. For illustrative purposes, we use the
WHO-CHOICE guidance of GDP per capita as a start-
ing CET but provide an online calculator that allows the
user to specify other CETs. In this paper we use the gen-
eric term HALY (health-adjusted life-years) to cover
both QALYs and DALYs. If the cost of the health inter-
vention to gain one HALY is less than the CET, then the
intervention is deemed cost-effective.
The estimated maximum intervention cost or EMIC
for a given age k was calculated using the following
formula:
EMIC ¼ A maxð Þ ¼ CET  HALY kð Þð Þ− C kð Þ
where A (max) is the theoretical maximum of one-off
direct cost of the life-saving health intervention, equiva-
lent to the EMIC for a given age k, and HALY (k) and C
(k) are the expected future HALYs and health system
costs for the person aged k years, respectively.
The components of the analysis, formula derivation,
model, and assumptions are outlined below.
Key components
The three main components in the analysis are health
system costs, health gains, and the cost-effectiveness
threshold.
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Health system costs
 The one-off or direct cost of the life-saving health
intervention itself is A.
 The estimated future health costs of the survivor
aged k years after the life-saving intervention is C(k),
assuming he/she then adopts the same morbidity
and mortality as the average citizen of the same
age and sex and thus incurs the same future health
system costs. This approach of considering future
health system costs in survivors is probably the
most appropriate one for modern health economic
analyses [26]. The cost of publicly funded health
services by age was from the New Zealand Ministry
of Health database, called “HealthTracker” [14].
HealthTracker is a collection of linked administrative
datasets of publicly funded health system events
(including hospitalizations, mortality, cancer
registrations, mental health and addiction service
use, pharmaceutical and laboratory claims,
primary health care enrollment, and outpatient/
emergency department visits) for the entire New
Zealand population with unit costs attached. But
due to gaps in HealthTracker data the costs were
scaled up across all age groups by 1.2. In addition, in
the last year of life costs were multiplied by 1.1, 1.2,
and 1.3 for the 65–74, 75–84, and 85+ age groups,
respectively, to capture the estimated missing data of
funding residential “disability
support services” care funded by the government
(Vote:Health) but not yet captured in available data.
 The total intervention cost for an individual aged
k years is then the one-off direct cost of the
intervention itself plus expected future health
spending: A + C(k).
Health gains
 The estimated future health gains of the survivor
aged k years after the life-saving intervention is
HALY (k). Health gain is captured in health-adjusted
life-years (HALYs), assuming he/she then adopts
the same morbidity and mortality as the average
citizen of the same age and sex and gains the same
future HALYs. The discounted future HALYs gained
is the same as the discounted health-adjusted life
expectancy (HALE) in this context. Incorporated
within the HALY calculation is population
background morbidity, in prevalent years of life
lived in disability (pYLDs). These pYLDs were
sourced from the New Zealand Burden of Disease
Study [13] and divided by the number of people
of the given sex and age to give an expected
or average morbidity per person.
Cost-effectiveness threshold (CET)
 For the CET, and in the absence of any official New
Zealand threshold, we used the rule-of-thumb
approach proposed by the World Health
Organization (WHO) as the departure point:
those interventions with a cost-effectiveness
ratio less than the country’s GDP per capita
can be considered very cost-effective [27]. For
this analysis, that equates to a conservative
cost-effectiveness threshold of NZ$45,000 per
HALY gained (for year 2011; $US30,000 adjusted
for OECD purchasing power parity [28]). Sensitivity
analyses using different CETs (NZ$20,000 and
NZ$100,000) were undertaken.
Formula derivation
Our basic premise is that in order for the maximum
amount invested up front to be cost-effective, the total
intervention cost per discounted HALY (otherwise
known as the incremental cost-effectiveness ratio or
ICER) has to be less than or equal to the CET.




Assume there is a hypothetical intervention that pre-
vents a death of a person aged k years with remaining
lifetime T years.
The expected future HALYs for the person aged k
years [HALY (k)] can be calculated as follows:
HALY kð Þ ¼
X∞
i¼k
1−pYLD ið Þ½ 
1þ rð Þi−kþ1  I T≥if g
Where pYLD is prevalent years of life lived in disability,
a population background morbidity measure expressed as
the average per person of a given sex and age. The dis-
count rate is r.
Similarly, the expected future health costs for the per-
son aged k years [C(k)] can be calculated as follows:




1þ rð Þi−kþ1  I T≥if g
I T≥if g ¼ 1; T≥i
0; T < i

Ci is the average annual health care cost of a New
Zealander aged i derived from the New Zealand Ministry
of Health’s HealthTracker data [29].
As stated earlier:
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Total Intervention Cost ¼ Aþ C kð Þ
Intervention HALE ¼ HALY kð Þ
On the other hand:
Comparator Cost ¼ 0
Comparator HALE ¼ 0
Therefore, the inequality (1) can be written as:
CET≥
Aþ C kð Þ−0
HALY kð Þ−0
From here it immediately follows that EMIC is equal
to A (max), solved from the equation below:
A maxð Þ ¼ CET  HALY kð Þð Þ− C kð Þ
Model
To calculate HALYs and costs, we modeled the New
Zealand population in 2011 with a simple, two-state
Markov model (“Alive”-“Dead”), in TreeAge Pro 2012.
The Markov model with an annual cycle followed the
cohort (in fact an individual with given age) up to
105 years old. We used New Zealand population mortal-
ity rates from Statistics New Zealand [30] to calculate
the probability of death. An individual with age i gener-
ates HALYs equal to 1-pYLD (i) and generates costs c (i)
for the health system. Discounted 1-pYLD (i) and c (i)
were assigned as health and cost “rewards” in the “Alive”
state. Hence the model returned HALYs and costs for
each modeled cohort. A 3 % discount rate was applied
to all future health system cost and health gains. Sensi-
tivity analyses of 0 % and 6 % were also conducted.
Assumptions
For the New Zealand-specific and ‘ideal’ EMIC results
that follow, we assume a hypothetical situation where
the risk of death is 100 % (i.e., the individual will die
without the intervention), this risk does not vary by age,
and the risk persists for a duration of one year. The life-
saving intervention is also assumed to be 100 % effective
(i.e., it eliminates the risk of death completely). We ap-
plied a 2 % annual reduction to New Zealand mortality
rates until 2026 and 1 % after that, to reflect improving
life expectancy over time (these patterns reflect long-run
mortality trends in the New Zealand context [31]). The
online EMIC calculator (see below), however, allows the
user to vary the anticipated decline in background mor-
tality, risk of death over time, and other variables such
as the risk of death without prevention or treatment
interventions.
Online calculator
The results that follow in the next section are specific to
New Zealand. In principle, this approach can be applied
to any other country as long as there are country-
specific data on age and sex-specific mortality, morbidity
(or combined as HALEs), and health system costs. Build-
ing on this idea, we have used available WHO data
on HALE and health system expenditure by country
[32, 33] to build an international EMIC calculator, avail-
able online at http://www.otago.ac.nz/wellington/research/
bode3/otago078632.html.
The international EMIC calculator potentially allows
researchers and policymakers to derive their own
country-specific EMICs by selecting their country from
a drop-down list, specifying the risk of death in the
disease being considered as well as the effectiveness of
the life-saving intervention, and selecting their preferred
cost-effectiveness threshold. The calculator is relatively
simplistic and users should be aware of several critical
assumptions, outlined in full in the Additional file 1 and
online user guide.
Results
The EMIC to save a life for the ideal intervention (100 %
fatal without intervention, 100 % effective intervention,
no ongoing morbidity, mortality risk, or cost increase
following intervention) varied markedly by age. Using
a 3 % discount rate, the EMIC was NZ$1.3 million to
save the life of a child, $0.8 million to save the life of
a 50-year-old, and $0.235 million to save the life of
an 80-year-old (Fig. 1, Table 1).
Table 1 shows HALEs, future health system (publicly
funded) costs, and corresponding EMICs by age. For ex-
ample, for a 15 to 19-year-old male, at a CET of
NZ$45,000 per HALY gained and a 3 % discount rate,
expected HALE is 26.2 years and expected future health
system (discounted) cost is $51,000. Hence, EMIC is
equal to (26.2 × $45,000) - $51,000 = $1,128,000. Figure 1
shows EMICs by age for different discount rates in
addition to the baseline rate of 3 % (i.e., 0 % and 6 %).
Sensitivity analyses show that the choice of the cost-
effectiveness threshold (from NZ$30,000 to NZ$60,000
per HALY) has a large impact on the EMIC (Fig. 1,
Table 2). This is especially the case for children. For ex-
ample, at a discount rate of 3 %, the EMIC for a child’s
life increases to $1.68 million (30 %) for a CET of
$60,000 and decreases to $0.82 million (36 %) for a
threshold of $30,000 (Table 2).
Discussion
Main findings and interpretation
This paper presents one possible approach to estimating
the maximum amount that a society could invest in a
life-saving health intervention, at different ages, while
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Fig. 1 Estimated maximum intervention cost to save a life, at NZ$45,000 cost-effectiveness threshold, for three different discount rates
Table 1 Life expectancy, health-adjusted life expectancy (HALE), health system costs, and estimated maximum intervention cost
(EMIC) at different discount rates
Age group Life expectancy
(years)
HALE (years) Future (public) health
system costs per individuala
per year (in thousands NZ$)
EMIC at a cost-effectiveness
threshold of NZ$45,000 per
HALY (in thousands NZ$)
Discount rate: 0 % 0 % 3 % 6 % 0 % 3 % 6 % 0 % 3 % 6 %
0-4 88.2 75.8 28.8 16.4 $209 $42 $17 $3,236 $1,288 $757
5-9 82.8 70.7 28.0 16.2 $203 $43 $17 $3,011 $1,274 $746
10-14 77.4 65.5 27.2 15.9 $198 $47 $19 $2,788 $1,237 $734
15-19 71.9 60.4 26.2 15.5 $193 $51 $21 $2,544 $1,172 $695
20-24 66.6 55.6 25.4 15.3 $187 $54 $23 $2,335 $1,133 $682
25-29 61.4 50.9 24.4 15.0 $181 $57 $26 $2,134 $1,093 $672
30-34 56.2 46.2 23.3 14.6 $174 $61 $28 $1,936 $1,050 $662
35-39 51.0 41.5 22.1 14.2 $168 $64 $31 $1,733 $994 $640
40-44 45.8 36.9 20.8 13.7 $161 $68 $35 $1,538 $936 $618
45-49 40.6 32.4 19.2 13.1 $154 $73 $40 $1,341 $865 $584
50-54 35.7 28.1 17.6 12.3 $147 $76 $45 $1,153 $789 $546
55-59 30.8 23.8 15.7 11.4 $139 $79 $51 $972 $707 $500
60-64 26.1 19.7 13.7 10.2 $129 $81 $55 $795 $612 $441
65-69 21.6 15.9 11.6 9.0 $117 $80 $58 $637 $521 $384
70-74 17.2 12.4 9.5 7.6 $101 $74 $57 $490 $424 $320
75-79 13.0 9.1 7.4 6.1 $82 $65 $53 $357 $327 $252
80-84 9.3 6.3 5.4 4.6 $64 $53 $46 $245 $235 $186
85-89 6.3 4.2 3.7 3.3 $46 $40 $36 $162 $161 $132
90-94 4.1 2.7 2.5 2.3 $31 $28 $26 $106 $108 $92
a Calculated at the midpoint of each age group, i.e., 2, 7,…, 92 years
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remaining cost-effective from a health system perspec-
tive (by a specified threshold). Our EMIC estimates
show marked variation by age: NZ$1.3 million
(US$880,000) to save the life of a child, $0.8 million
(US$540,000) to save the life of a 50-year-old, and
$0.235 million (US$158,000) to save the life of an 80-
year-old, for the scenario where death was inevitable and
the intervention 100 % effective with no sequelae. The
variation by age is not surprising given the central role
that remaining life expectancy plays within a metric like
health-adjusted life expectancy.
Although this case study used New Zealand data, this
approach could potentially be employed in any other
country as long as data on age and sex-specific mortal-
ity, morbidity (or combined as HALEs), and health sys-
tem expenditure are available. HALE data are now
readily available for many countries, for example from
the recent Global Burden of Disease 2010 study [34].
The expected stream of future health spending is less
readily available, although this is likely to change with
the increasing linkage of health and costing datasets –
and “like” country data can be used as a substitute.
Using available WHO data, we have extended this ana-
lysis by building an international EMIC calculator that
allows the user to apply this approach to specific coun-
tries (albeit under several critical assumptions). Results
for other countries should, however, be used cau-
tiously with due regard for the various limitations
with EMIC calculations (as detailed further below and
in the Additional file 1).
How might EMIC results be used?
Policymakers often need to make decisions about which
new health interventions to adopt or reject, and often
quickly. These decisions are and should be based on
multiple criteria, of which cost-effectiveness is just one
(as detailed in the Introduction). But it is envisioned that
calculating an EMIC for a possible intervention might
be potentially useful as a rapid screening process. Obvi-
ously cost-effective interventions should be implemented
and cost-ineffective interventions pursued no further,
and borderline interventions should subjected to more
thorough cost-effectiveness analyses. Moreover, EMICs
might be useful in planning research, as researchers can
determine whether the treatment or preventive interven-
tion they are working on is likely to be less than the
EMIC for a given society. For example, using these New
Zealand results, if a life-saving intervention appears
likely to cost many times more than NZ$1.3 million per
life saved, then it is unlikely to be found cost-effective
upon further, more detailed research in this setting for
any age group (using a threshold of NZ$45,000 per
Table 2 Estimated maximum intervention cost (EMIC in millions NZ$) at different levels of cost-effectiveness threshold that reflect
willingness-to-pay to save a HALY (at the 3 % discount rate)
Age group Cost-effectiveness threshold for gaining a HALY
$20,000 $30,000 $40,000 $50,000 $60,000 $70,000 $80,000 $90,000 $100,000
0-4 0.53 0.82 1.11 1.40 1.68 1.97 2.26 2.55 2.84
5-9 0.51 0.79 1.07 1.35 1.63 1.92 2.20 2.48 2.76
10-14 0.49 0.76 1.03 1.30 1.57 1.85 2.12 2.39 2.66
15-19 0.46 0.73 0.99 1.25 1.51 1.78 2.04 2.30 2.56
20-24 0.44 0.69 0.95 1.20 1.45 1.71 1.96 2.21 2.47
25-29 0.41 0.66 0.90 1.14 1.39 1.63 1.88 2.12 2.37
30-34 0.39 0.62 0.85 1.09 1.32 1.55 1.79 2.02 2.25
35-39 0.37 0.59 0.81 1.03 1.25 1.47 1.70 1.92 2.14
40-44 0.36 0.57 0.78 0.98 1.19 1.40 1.61 1.81 2.02
45-49 0.35 0.55 0.74 0.93 1.12 1.32 1.51 1.70 1.89
50-54 0.32 0.50 0.67 0.85 1.02 1.20 1.37 1.55 1.73
55-59 0.28 0.44 0.60 0.75 0.91 1.07 1.23 1.38 1.54
60-64 0.24 0.38 0.52 0.65 0.79 0.93 1.07 1.20 1.34
65-69 0.20 0.32 0.43 0.55 0.67 0.78 0.90 1.02 1.13
70-74 0.16 0.26 0.35 0.44 0.54 0.63 0.73 0.82 0.92
75-79 0.12 0.19 0.27 0.34 0.41 0.49 0.56 0.63 0.71
80-84 0.08 0.13 0.19 0.24 0.29 0.35 0.40 0.45 0.51
85-89 0.04 0.08 0.12 0.16 0.19 0.23 0.27 0.30 0.34
90-94 0.02 0.05 0.07 0.10 0.12 0.15 0.17 0.20 0.22
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HALY). Along the same lines, if a potential intervention
appears to be likely to cost many times more than
NZ$400,000 per life saved, further research may be un-
likely to find it cost-effective in the 70-plus age group.
It is plausible that calculator-produced EMIC results
could help with decision-making in a public health emer-
gency, e.g., purchasing a new vaccine in the face of a pan-
demic emergency. But ideally documents such as pandemic
plans should have analyses that are worked through in
advance and cover a wide range of contingencies.
Strengths and limitations of this study?
This study was able to use detailed epidemiological and
health system costing data for one country. The EMIC
values produced are age-specific and can reflect policy-
maker preferences around such aspects as discount
rates, CET values, and future mortality trends. Further-
more, with the international EMIC calculator, EMIC es-
timates can be “customized” using country-specific
mortality data, morbidity data, and health system costs,
as well as permitting different CET values. Nevertheless,
we recognize that this EMIC approach builds on the
commonly used metrics of health economics (HALE,
QALYs, and DALYs) which value future life expectancy
and hence favor interventions aimed at younger ages. As
such, a society that rejected any such weighting based
on the magnitude of (discounted) remaining expected
life expectancy should not use this type of approach.
Nevertheless, for those societies that already use such
metrics as QALYs and DALYs in health policymaking
and which have explicit or implicit thresholds for deter-
mining what interventions are “cost-effective,” there is a
logical coherence with using the EMIC approach as out-
lined here.
In our initial analyses, we used the CET approach from
WHO-CHOICE (i.e., using a country’s GDP per capita
for a HALY gained). Such an approach has been appro-
priately criticized (e.g., by Revill et al. [35], Newall et al.
[36], and Marseille et al. [37]), and a particular weakness
is that it is not linked to the shadow price of a health
system’s budget constraint. But in the absence of viable
alternative options, we used this approach as it still pro-
vides some indicator (albeit fairly crude) of the size of
the resources that a country can draw upon to invest in
health interventions. Furthermore, users are able to alter
the CET as they see fit in the online calculator.
A further limitation of the EMIC approach is that it
does not take into account any side effects of the inter-
vention or any permanent morbidity sequelae or altered
mortality risk among people whose life was saved. Such
conditions will reduce the HALYs gained and therefore
also reduce the amount that health system policymakers
would be willing to spend on the intervention for a given
CET. As stated earlier, it is not so applicable to chronic
diseases that reduce life expectancy, but rather is best
when considering relatively acute, “short and sharp” dis-
eases or injuries, where the intervention that saves the
lives of individuals then typically returns them to ex-
pected health.
Potential further research and country-specific adaptation
Given the limitations outlined above, it would be ideal if
different societies conducted research on whether or not
their populations value life differently across the life
course or if they philosophically object to any such dif-
ferentials. This could be explored with surveys of values
or potentially with citizen juries [38]. Similar means can
be used to determine the appropriate discount rate to
use for country-specific health system decision-making.
In terms of the use of the EMIC results produced here
and from the online calculator, it would be useful to re-
search the utility of these for busy policymakers. Does
this information allow for the use of limited health eco-
nomic modeling research resources to be better tar-
geted? Or will policymakers find the residual uncertainty
too large to make any such early calls about not
researching the cost-effectiveness of potential interven-
tions further?
Finally, in the New Zealand setting, there is a need for
ongoing refinements in health system costs as outlined
in a 2014 article [14] and subsequent work on health
costs (submitted for publication in 2015). Moreover, for
international applications of the EMIC, country-specific
cost data would be ideal, or at least some knowledge as
to whether New Zealand cost data can be appropriately
scaled up or down.
In conclusion, we present a possible approach to esti-
mating maximal cost-effective investment in life-saving
health interventions, under various assumptions and
scenarios. Our online calculator allows this approach to
be applied for a range of user-specified assumptions and
inputs and in other countries. Despite the various limita-
tions with this work, busy policymakers could use these
estimates as a rapid screening tool. This could determine
if more detailed cost-effectiveness analyses of potential
life-saving interventions might be worthwhile or which
proposed interventions are very unlikely to benefit from
such additional research.
Additional file
Additional file 1: Outline and assumptions of the International
EMIC calculator.
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